Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22893643 | 0.88 | OPRM1 (0.51) | L3MBTL1LMNAALDH1A1POLBHSD17B10 | |
| SCHEMBL15565306 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CHRM3CHRM4LMNA | |
| SCHEMBL20487147 | 0.82 | L3MBTL1 (0.42) | L3MBTL1LMNAALDH1A1POLBHSD17B10 | |
| SCHEMBL20488330 | 0.81 | JAK2 (0.46) | L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL20487581 | 0.81 | JAK2 (0.46) | L3MBTL1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL25663657 | 0.75 | SLC6A2 (0.40) | CHRM2CHRM1CHRM3CHRM4LMNA | |
| SCHEMBL11165873 | 0.73 | L3MBTL1 (0.59) | L3MBTL1LMNAALDH1A1POLBHSD17B10 | |
| SCHEMBL6363989 | 0.73 | L3MBTL1 (0.59) | L3MBTL1LMNAALDH1A1POLBHSD17B10 | |
| SCHEMBL25663636 | 0.73 | SIGMAR1 (0.40) | CHRM2CHRM1CHRM3LMNAALDH1A1 | |
| SCHEMBL3632576 | 0.72 | L3MBTL1 (0.54) | L3MBTL1LMNAALDH1A1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2882725-A1 | SUBSTITUTED HETERO-AZEPINONES | F. Hoffmann-La Roche AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| CN-104470905-A | Substituted hetero-azepinones | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | L3MBTL1 1802/4885CHRM2 701/4885CHRM1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.